ObsEva SA Forecasted to Post Q3 2017 Earnings of ($0.65) Per Share (OBSV)
ObsEva SA (NASDAQ:OBSV) – Jefferies Group decreased their Q3 2017 earnings per share (EPS) estimates for shares of ObsEva SA in a report released on Wednesday. Jefferies Group analyst B. Amin now anticipates that the company will post earnings of ($0.65) per share for the quarter, down from their prior forecast of ($0.56). Jefferies Group also issued estimates for ObsEva SA’s Q4 2017 earnings at ($0.68) EPS, FY2017 earnings at ($2.52) EPS, FY2018 earnings at ($2.67) EPS, FY2019 earnings at ($2.64) EPS, FY2020 earnings at ($2.30) EPS and FY2021 earnings at ($3.06) EPS.
ObsEva SA (NASDAQ:OBSV) last announced its quarterly earnings data on Tuesday, August 15th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by $0.13. During the same quarter last year, the business earned ($0.30) earnings per share.
OBSV has been the subject of a number of other reports. Zacks Investment Research raised ObsEva SA from a “sell” rating to a “hold” rating in a report on Wednesday, July 19th. Leerink Swann reaffirmed an “outperform” rating and set a $18.00 price target on shares of ObsEva SA in a report on Wednesday. Finally, HC Wainwright set a $27.00 price target on ObsEva SA and gave the stock a “buy” rating in a report on Wednesday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $23.25.
ObsEva SA (OBSV) opened at 7.74 on Friday. The stock has a 50 day moving average price of $7.97 and a 200-day moving average price of $9.10. The firm’s market capitalization is $206.06 million. ObsEva SA has a one year low of $5.00 and a one year high of $14.69.
Several hedge funds have recently bought and sold shares of the company. Baker Avenue Asset Management LP purchased a new stake in ObsEva SA during the first quarter worth approximately $104,000. Paloma Partners Management Co purchased a new stake in ObsEva SA during the first quarter worth approximately $131,000. Sphera Funds Management LTD. boosted its stake in ObsEva SA by 9.7% in the second quarter. Sphera Funds Management LTD. now owns 231,497 shares of the company’s stock worth $1,979,000 after buying an additional 20,411 shares during the period. Iguana Healthcare Management LLC purchased a new stake in ObsEva SA during the first quarter worth approximately $260,000. Finally, Spark Investment Management LLC purchased a new stake in ObsEva SA during the first quarter worth approximately $518,000. Institutional investors and hedge funds own 49.11% of the company’s stock.
ObsEva SA Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.